Author

Bernd Jahrsdörfer

Professor f

Biography

Bernd Jahrsdörfer is currently working as a Professor in the Department of Immunology, Clinical Pharmacology. His research interests includes Immunology, Pharmacology, Clinical research. He is serving as an editorial member and reviewer of several international reputed journals. He has successfully completed his Administrative responsibilities. Bernd Jahrsdörfer has authored of many research articles/books related to Pharmacology.  
Title
Cited by
Year
SARS-CoV-2 variants B. 1.351 and P. 1 escape from neutralizing antibodies
M Hoffmann, P Arora, R Groß, A Seidel, BF Hörnich, AS Hahn, N Krüger, ...Cell 184 (9), 2384-2393. e12, 2021202
857
2021
Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients
A Sattler, E Schrezenmeier, UA Weber, A Potekhin, F Bachmann, ...The Journal of clinical investigation 131 (14), 2021202
215
2021
Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients
H Rincon-Arevalo, M Choi, AL Stefanski, F Halleck, U Weber, F Szelinski, ...Science immunology 6 (61), eabj1031, 2021202
213
2021
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
R Groß, M Zanoni, A Seidel, C Conzelmann, A Gilg, D Krnavek, ...EBioMedicine 75, 2022202
122
2022
B and T cell responses after a third dose of SARS-CoV-2 vaccine in kidney transplant recipients
E Schrezenmeier, H Rincon-Arevalo, AL Stefanski, A Potekhin, ...Journal of the American Society of Nephrology 32 (12), 3027-3033, 2021202
72
2021
SARS-CoV-2 variants B. 1.351 and B. 1.1. 248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination
M Hoffmann, P Arora, R Groß, A Seidel, B Hörnich, A Hahn, N Krüger, ...BioRxiv, 2021.02. 11.430787, 2021202
57
2021
B Cell Numbers Predict Humoral and Cellular Response Upon SARS–CoV‐2 Vaccination Among Patients Treated With Rituximab
AL Stefanski, H Rincon‐Arevalo, E Schrezenmeier, K Karberg, F Szelinski, ...Arthritis & Rheumatology 74 (6), 934-947, 2022202
54
2022
Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination–specific humoral and cellular immunity in kidney transplant recipients
E Schrezenmeier, H Rincon-Arevalo, A Jens, AL Stefanski, C Hammett, ...JCI insight 7 (9), 2022202
54
2022
Independent side-by-side validation and comparison of 4 serological platforms for SARS-CoV-2 antibody testing
B Jahrsdörfer, J Kroschel, C Ludwig, VM Corman, T Schwarz, S Körper, ...The Journal of Infectious Diseases 223 (5), 796-801, 2021202
47
2021
Robust and durable serological response following pediatric SARS-CoV-2 infection
H Renk, A Dulovic, A Seidel, M Becker, D Fabricius, M Zernickel, D Junker, ...Nature Communications 13 (1), 128, 2022202
41
2022
mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects
D Fabricius, C Ludwig, J Scholz, I Rode, C Tsamadou, EM Jacobsen, ...Vaccines 9 (8), 918, 2021202
39
2021
An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection
C Conzelmann, A Gilg, R Groß, D Schuetz, N Preising, L Ständker, ...Antiviral Research 181, 104882, 2020202
36
2020
Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—a new target for lupus treatment
N Smith, MP Rodero, N Bekaddour, V Bondet, YB Ruiz-Blanco, M Harms, ...Science Advances 5 (7), eaav9019, 2019201
31
2019
Characterization of the SARS-CoV-2 neutralization potential of COVID-19–convalescent donors
B Jahrsdörfer, R Groß, A Seidel, L Wettstein, C Ludwig, T Schwarz, ...The Journal of Immunology 206 (11), 2614-2622, 2021202
23
2021
Donors for SARS-CoV-2 convalescent plasma for a controlled clinical trial: donor characteristics, content and time course of SARS-CoV-2 neutralizing antibodies
S Körper, B Jahrsdörfer, VM Corman, J Pilch, P Wuchter, R Blasczyk, ...Transfusion Medicine and Hemotherapy 48 (3), 137-147, 2021202
19
2021
Typically asymptomatic but with robust antibody formation: Children’s unique humoral immune response to SARS-CoV-2
H Renk, A Dulovic, M Becker, D Fabricius, M Zernickel, D Junker, A Seidel, ...medRxiv, 2021.07. 20.21260863, 2021202
15
2021
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients
S Körper, B Grüner, D Zickler, T Wiesmann, P Wuchter, R Blasczyk, ...The Journal of clinical investigation 132 (24), 2022202
12
2022
BNT162b2 Vaccination elicits strong serological immune responses against SARS-CoV-2 including variants of concern in elderly convalescents
B Jahrsdörfer, D Fabricius, J Scholz, C Ludwig, A Grempels, R Lotfi, ...Frontiers in Immunology 12, 743422, 2021202
11
2021
Impaired antigen-specific memory B cell and plasma cell responses including lack of specific IgG upon SARS-CoV-2 BNT162b2 vaccination among Kidney Transplant and Dialysis patients
H Rincon-Arevalo, M Choi, AL Stefanski, F Halleck, U Weber, F Szelinski, ...medRxiv, 2021.04. 15.21255550, 2021202
10
2021
Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients
E Schrezenmeier, H Rincon-Arevalo, A Jens, AL Stefanski, C Hammett, ...medRxiv, 2022.01. 05.21268478, 2022202
9
2022

Referred From: https://scholar.google.de/citations?user=q6uROkUAAAAJ&hl=de

Cited by
Citations 8966
h-index 35
i10-index 50
Recommended Journals
Open Access Journals